ArriVent BioPharma (AVBP) Stock Overview
A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AVBP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ArriVent BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$29.71 |
| 52 Week Low | US$15.47 |
| Beta | 0 |
| 1 Month Change | -15.76% |
| 3 Month Change | 4.26% |
| 1 Year Change | -24.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.00% |
Recent News & Updates
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy
Jan 04Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation
Nov 13
Recent updates
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy
Jan 04Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation
Nov 13Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Invest In Growth?
May 21We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
Jan 11We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth
Sep 24ArriVent BioPharma: Bringing A Novel Cancer Drug From China
Sep 17ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
Jan 29Shareholder Returns
| AVBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | -2.0% | -1.0% |
| 1Y | -24.4% | 23.0% | 14.9% |
Return vs Industry: AVBP underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: AVBP underperformed the US Market which returned 14.9% over the past year.
Price Volatility
| AVBP volatility | |
|---|---|
| AVBP Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AVBP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVBP's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 52 | Bing Yao | arrivent.com |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors.
ArriVent BioPharma, Inc. Fundamentals Summary
| AVBP fundamental statistics | |
|---|---|
| Market cap | US$858.65m |
| Earnings (TTM) | -US$150.98m |
| Revenue (TTM) | n/a |
Is AVBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$150.98m |
| Earnings | -US$150.98m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVBP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 13:25 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ArriVent BioPharma, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Justin Zelin | BTIG |